Related Experiment Video
Updated: Jul 27, 2025
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
Published on: May 9, 2025
Pharmacological inhibition of MDM4 alleviates pulmonary fibrosis
Qianru Mei1, Zhenhua Yang1, Zhengkai Xiang2
1School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Abstract:
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease of unknown etiology with no cure. A better understanding of the disease processes and identification of druggable targets will benefit the development of effective therapies for IPF. We previously reported that MDM4 promoted lung fibrosis through the MDM4-p53-dependent pathway. However, it remained unclear whether targeting this pathway would have any therapeutic potential. In this study, we evaluated the efficacy of XI-011, a small molecular inhibitor of MDM4, for treating lung fibrosis. We found that XI-011 significantly reduced MDM4 expression and increased the expression of total and acetylated p53 in primary human myofibroblasts and a murine fibrotic model. XI-011 treatment resulted in the resolution of lung fibrosis in mice with no notable impact on normal fibroblast death or the morphology of healthy lungs. Based on these findings, we propose that XI-011 might be a promising therapeutic drug candidate for treating pulmonary fibrosis.
Insights
A new drug, XI-011, effectively treats lung fibrosis by targeting the MDM4-p53 pathway. This research shows promise for developing novel therapies for idiopathic pulmonary fibrosis (IPF).
Area of Science:
- Pulmonology
- Oncology
- Pharmacology
Background:
- Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease with no cure, necessitating research into disease mechanisms and therapeutic targets.
- Previous work identified MDM4 as a promoter of lung fibrosis via the MDM4-p53 pathway, suggesting this pathway as a potential therapeutic target.
Purpose of the Study:
- To evaluate the therapeutic efficacy of XI-011, a novel small molecule inhibitor of MDM4, in treating lung fibrosis.
- To determine if targeting the MDM4-p53 pathway with XI-011 can resolve established lung fibrosis.
Main Methods:
- Treatment of primary human myofibroblasts and a murine model of lung fibrosis with XI-011.
- Assessment of MDM4 expression and p53 levels (total and acetylated) following XI-011 treatment.
- Evaluation of fibrotic resolution and impact on normal lung fibroblasts and tissue morphology in the murine model.
Main Results:
- XI-011 significantly reduced MDM4 expression and increased total and acetylated p53 levels in both human myofibroblasts and the murine fibrotic model.
- XI-011 treatment led to the resolution of lung fibrosis in mice.
- No significant impact on normal fibroblast viability or the morphology of healthy lung tissue was observed.
Conclusions:
- XI-011 demonstrates efficacy in resolving lung fibrosis in a preclinical model.
- Targeting the MDM4-p53 pathway with XI-011 represents a promising therapeutic strategy for idiopathic pulmonary fibrosis.
- XI-011 may be a potential drug candidate for the treatment of pulmonary fibrosis.
Related Concept Videos
02:23Abnormal Proliferation
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...